-
04.27.2026 | AMR musical is the ‘beginning’ of a movement to protect antibiotics
THE PHARMACIST | A musical raising awareness of antimicrobial resistance (AMR) is the beginning of a ‘true movement’ to safeguard antibiotics, a former chief medical officer has said.
-
04.24.2026 | Johns Hopkins spinout Pearl Diagnostics raises $11.2M to bring infection screening to market
Pearl Diagnostics just completed a Series A round to help bring its noninvasive fungal infection test to market after a recent Food and Drug Administration clearance.
-
04.23.2026 | From clinic to doorstep: How Visby Medical is rewriting the rules of diagnostics
The US healthcare system was built for patients, but Visby is rebuilding it for consumers.
-
04.15.2026 | Why the antimicrobial resistance crisis is bigger than cancer and how Immunethep is thinking differently
We’ve been hearing about the Antimicrobial Resistance (AMR) crisis for over a decade. Yet, according to Bruno Santos (CEO) and Pedro Madureira (CSO), co-founders of Immunethep, the public still hasn’t grasped the gravity of the situation.
-
04.09.2026 | Seres Therapeutics to present at CARB-X Investor Day
Seres Therapeutics, Inc. a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the ESCMID Global conference in Munich, Germany.
-
04.09.2026 | Vedanta Biosciences showcases innovative work on its microbiome-based therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 Global Congress
Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced a poster presentation related to the company’s work on VE303.
-
04.09.2026 | Basilea lands US$6m CARB X boost for novel antibiotic
Amid chronic under-investments in new antibacterial weapons, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative antibiotic now entering early clinical development.
-
04.06.2026 | Portugal’s biotech industry is growing up
For years, Portugal sat just outside Europe’s main biotech conversation: scientifically credible, strong in research, but too small, too fragmented and too thinly financed to compete with the established hubs in Switzerland, the UK, France, Germany or the Nordics.
-
04.03.2026 | Vedanta Biosciences announces the Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection will continue as planned following protocol-specified interim analysis
Independent data monitoring committee recommendation was based on review of safety and efficacy; enrollment expected to complete in 2H 2026
-
04.02.2026 | Clarametyx Biosciences strengthens executive leadership to accelerate clinical development efforts
Veronica Hall, PhD, has been promoted to Chief Development Officer and Head of R&D and Brendan Doran, PharmD, has been promoted to Chief Operating Officer.
-
03.23.2026 | Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the dosing of the first healthy volunteer in the first-in-human phase 1 study of BAL2420, evaluating the safety, tolerability and pharmacokinetics of this lipopolysaccharide transport protein A (LptA) inhibitor.
-
03.19.2026 | Pattern Bioscience surpasses 1,000 samples in multi-center clinical trial of rapid pneumonia diagnostic
Milestone marks the half-way point of enrollment in pivotal U.S. study designed to support 510(k) submission for the first culture-free, rapid phenotypic ID/AST panel for critically ill pneumonia patients.
-
03.18.2026 | Ten Swiss biotech startups selected for Boston roadshow
Ten startups have been selected for the 2026 Venture Leaders Biotech program, which will take them to Boston from May 31st to June 5th as part of the Swiss National Startup Team.
-
03.11.2026 | Gram-negative bacterial infection treatment gets QIDP status
The US Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to a novel treatment of Gram-negative bacterial infections.
-
03.10.2026 | Peptilogics begins trial of drug designed to cure medical device-related infections
A clinical trial testing a first-in-class drug designed to combat infections from medical devices has enrolled its first patient at the University of Cincinnati Medical Center, Peptilogics announced.
-
03.04.2026 | CARB-X funds research into new approach for drug-resistant bacteria
CARB-X announced today that it’s awarding $1.2 million to a research team at Harvard University to develop enhanced antibiotics for multidrug-resistant bacteria.
-
03.03.2026 | CRISPR-armed phages clear first human safety bar
With phase 1 data published today in The Lancet Microbe, SNIPR is positioning its experimental CRISPR–Cas-armed phage cocktail, SNIPR001, not simply as a novel anti-infective, but as the clinical proof point for an entirely new category of precision antimicrobials.
-
02.25.2026 | Innovative antibiotic candidate gets funding boost
British immunotherapy company Centauri Therapeutics yesterday announced a ₤6 million ($8.1 million USD) investment from the AMR Action Fund to support development of its broad-spectrum antibiotic candidate.
-
02.25.2026 | Centauri extends Series A to £30M with AMR Action Fund to fight drug-resistant infections
UK-based biotech Centauri Therapeutics is advancing its leading antimicrobial program. The immunotherapy company has secured a £6 million investment from the AMR Action Fund, extending its Series A round to £30 million.
-
02.24.2026 | Cheshire-based biotech scores £30m Series A round
Centauri Therapeutics, a biotech company based in Cheshire’s Alderley Park, has secured a £30m Series A funding round to support the completion of clinical studies for its antimicrobial treatments.
-
02.23.2026 | Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine
ETH spin-off Baxiva has obtained CHF 150,000 from Venture Kick to advance a new vaccine designed to prevent diseases caused by Escherichia coli (E. coli).
-
02.11.2026 | TIME100 Health: Adam de la Zerda
Unlike other at-home STI tests, which require shipping samples to labs, Visby Medical’s new FDA-approved 3-in-1 women’s test for gonorrhea, chlamydia, and trichomoniasis is a miniaturized PCR machine that runs tests just as accurately in 30 minutes.
-
02.06.2026 | Chembio receives $1.8 million CARB-X grant to develop a rapid diagnostic test for typhoid fever
Chembio Diagnostic Systems, Inc. (Chembio), a wholly owned subsidiary of Biosynex, a leader in point-of-care (POC) diagnostics, today announced that it has been awarded a $1.8 million grant from CARB-X to support the development of a rapid point-of-care diagnostic test for acute typhoid fever.
-
02.05.2026 | CARB-X funds development of rapid test for typhoid fever
CARB-X announced today that it’s awarding Chembio Diagnostic Systems $1.8 million to support the development of a rapid, finger stick–based diagnostic test for typhoid fever.
-
02.05.2026 | CARB-X to support development of typhoid fever diagnostic from Chembio
CARB-X is awarding US$1.8 million to Chembio Diagnostic Systems, Inc. to develop a rapid point-of-care test for the detection of Immunoglobulin A (IgA) antibodies to diagnose acute infection of Salmonella enterica serovar Typhi.
-
02.05.2026 | CARB-X awards $1.8M for Chembio Diagnostic Systems typhoid fever dx
CARB-X announced on Thursday that it has awarded $1.8 million to Biosynex subsidiary Chembio Diagnostic Systems to support the development of a rapid test for typhoid fever.
-
02.05.2026 | Visby Medical, Watchmaker Genomics partner to develop at-home respiratory pathogen detection tests
Visby Medical said on Thursday that it has inked a partnership with Watchmaker Genomicsto develop diagnostic tests for detecting respiratory pathogens in the at-home setting.
-
01.27.2026 | Clarametyx Biosciences strengthens scientific advisory board with expert appointments to advance pipeline programs
Drs. Bruce Forrest, George Siber, Obadiah Plante and David Zarley appointed to guide Clarametyx’s anti-biofilm technologies for chronic respiratory disease.
-
01.21.2026 | Replik: Ny satsning från Gates Foundation
Stefan Swartling Peterson, Otto Cars och medförfattare uppmanar Bill Gates att bidra i kampen mot antibiotikaresistens .
-
01.20.2026 | Topline results: Antibody therapy lowers inflammatory biomarkers in cystic fibrosis
In patients with cystic fibrosis, CMTX-101, an immune-enabling antibody therapy, lowered four inflammatory biomarkers and Pseudomonas aeruginosa burden vs. standard of care, according to phase 1b/2a trial topline results.
-
01.19.2026 | GARDP and Debiopharm partner to advance antibiotic for drug-resistant gonorrhea
The partnership is a global collaboration to develop Debio1453, a first-in-class antibiotic targeting multidrug-resistant gonorrhea, aiming to strengthen the fragile antibiotic pipeline and ensure future treatment options.
-
01.09.2026 | Clarametyx Biosciences announces positive topline data from Phase 2a study evaluating CMTX-101 in cystic fibrosis
CMTX-101 treatment produced clinically meaningful reductions in key inflammatory biomarkers and pulmonary Pseudomonas aeruginosa burden, and preservation of pulmonary function.
-
01.08.2026 | Quest, Labcorp add fully at-home STI test to women’s health offerings
Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the potential demand for quick, at-home testing for women’s sexual health.
Toggle navigation